Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population.

Sánchez-Conde M, Rodriguez-Centeno J, Dronda F, López JC, Jiménez Z, Berenguer J, Pérez-Elías MJ, Moreno S, Rodés B, Brañas F.

Epigenomics. 2019 Apr;11(5):501-509. doi: 10.2217/epi-2018-0130. Epub 2019 Jan 24.

PMID:
30675812
2.

Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.

Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ ANRS 143 Study Group.

J Infect Dis. 2018 Oct 5;218(10):1523-1530. doi: 10.1093/infdis/jiy399.

PMID:
29982509
3.

Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults.

Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-Garcia J, Rodriguez-Centeno J, Rodes B, Cantos AE, Alejos B, de Miguel R, Arnalich F, Perona R, Arribas JR.

J Infect Dis. 2018 Oct 5;218(10):1531-1540. doi: 10.1093/infdis/jiy364.

PMID:
29912427
4.

Expression profiling of chromatin-modifying enzymes and global DNA methylation in CD4+ T cells from patients with chronic HIV infection at different HIV control and progression states.

Bogoi RN, de Pablo A, Valencia E, Martín-Carbonero L, Moreno V, Vilchez-Rueda HH, Asensi V, Rodriguez R, Toledano V, Rodés B.

Clin Epigenetics. 2018 Feb 13;10:20. doi: 10.1186/s13148-018-0448-5. eCollection 2018.

5.

Short Communication: p21/CDKN1A Expression Shows Broad Interindividual Diversity in a Subset of HIV-1 Elite Controllers.

de Pablo A, Bogoi R, Bejarano I, Toro C, Valencia E, Moreno V, Martín-Carbonero L, Gómez-Hernando C, Rodés B.

AIDS Res Hum Retroviruses. 2016 Mar;32(3):232-6. doi: 10.1089/AID.2015.0137. Epub 2015 Dec 2.

PMID:
26537458
6.

Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides.

Briz V, Sepúlveda-Crespo D, Diniz AR, Borrego P, Rodes B, de la Mata FJ, Gómez R, Taveira N, Muñoz-Fernández MÁ.

Nanoscale. 2015 Sep 21;7(35):14669-83. doi: 10.1039/c5nr03644e. Epub 2015 Aug 14.

PMID:
26274532
7.

Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy.

Palacios JA, Pérez-Piñar T, Toro C, Sanz-Minguela B, Moreno V, Valencia E, Gómez-Hernando C, Rodés B.

J Virol. 2012 Dec;86(23):13081-4. doi: 10.1128/JVI.01741-12. Epub 2012 Sep 12.

8.

Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A.

Faria NR, Hodges-Mameletzis I, Silva JC, Rodés B, Erasmus S, Paolucci S, Ruelle J, Pieniazek D, Taveira N, Treviño A, Gonçalves MF, Jallow S, Xu L, Camacho RJ, Soriano V, Goubau P, de Sousa JD, Vandamme AM, Suchard MA, Lemey P.

J Gen Virol. 2012 Apr;93(Pt 4):889-99. doi: 10.1099/vir.0.038638-0. Epub 2011 Dec 21.

9.

An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.

Damond F, Benard A, Balotta C, Böni J, Cotten M, Duque V, Ferns B, Garson J, Gomes P, Gonçalves F, Gottlieb G, Kupfer B, Ruelle J, Rodes B, Soriano V, Wainberg M, Taieb A, Matheron S, Chene G, Brun-Vezinet F; ACHI(E)V(2E) Study Group.

J Clin Microbiol. 2011 Oct;49(10):3491-7. doi: 10.1128/JCM.02389-10. Epub 2011 Aug 3.

10.

Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors.

Salgado M, Rallón NI, Rodés B, López M, Soriano V, Benito JM.

Clin Immunol. 2011 May;139(2):110-4. doi: 10.1016/j.clim.2011.02.008. Epub 2011 Mar 2.

PMID:
21367666
11.

Characterization of host genetic expression patterns in HIV-infected individuals with divergent disease progression.

Salgado M, López-Romero P, Callejas S, López M, Labarga P, Dopazo A, Soriano V, Rodés B.

Virology. 2011 Mar 1;411(1):103-12. doi: 10.1016/j.virol.2010.12.037. Epub 2011 Jan 15.

12.

An additive effect of protective host genetic factors correlates with HIV nonprogression status.

Salgado M, Simón A, Sanz-Minguela B, Rallón NI, López M, Vicario JL, Benito JM, Rodés B.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):300-5. doi: 10.1097/QAI.0b013e3182036f14.

PMID:
21084992
13.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M.

Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science.1195271. Epub 2010 Nov 4.

14.

Molecular characterization of human T cell leukemia virus type 1 subtypes in a group of infected individuals diagnosed in Portugal and Spain.

Pádua E, Rodés B, Pérez-Piñar T, Silva AF, Jiménez V, Ferreira F, Toro C.

AIDS Res Hum Retroviruses. 2011 Mar;27(3):317-22. doi: 10.1089/aid.2010.0195. Epub 2010 Oct 18.

PMID:
20950257
15.

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

Salgado M, Toro C, Simón A, Garrido C, Blanco F, Soriano V, Rodés B.

J Clin Virol. 2009 Oct;46(2):173-5. doi: 10.1016/j.jcv.2009.06.020. Epub 2009 Jul 22.

PMID:
19625211
16.

Lack of significant cross-reactivity for HIV-2 immunoblots in HIV-1-infected patients.

Amor A, Simón A, Salgado M, Rodés B, Soriano V, Toro C.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):339-40. doi: 10.1097/QAI.0b013e318193900d. No abstract available.

PMID:
19242265
17.

No major differences in the functional profile of HIV Gag and Nef-specific CD8+ responses between long-term nonprogressors and typical progressors.

López M, Soriano V, Lozano S, Ballesteros C, Cascajero A, Rodés B, De La Vega E, González-Lahoz J, Benito JM.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1185-95. doi: 10.1089/aid.2008.0006.

PMID:
18729773
18.

Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.

Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, Rodes B, Albert J, Böni J, Garson J, Ferns B, Matheron S, Chene G, Brun-Vezinet F; ACHIEV2E Collaboration on HIV-2 Infection Study Group.

J Clin Microbiol. 2008 Jun;46(6):2088-91. doi: 10.1128/JCM.00126-08. Epub 2008 Apr 23.

19.

Elite HIV controllers: myth or reality?

Saksena NK, Rodes B, Wang B, Soriano V.

AIDS Rev. 2007 Oct-Dec;9(4):195-207. Review.

PMID:
18219363
20.

Molecular characterization and analysis of a gene encoding the acidic repeat protein (Arp) of Treponema pallidum.

Liu H, Rodes B, George R, Steiner B.

J Med Microbiol. 2007 Jun;56(Pt 6):715-21.

PMID:
17510254
21.

Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.

Humbert M, Antoni S, Brill B, Landersz M, Rodes B, Soriano V, Wintergerst U, Knechten H, Staszewski S, von Laer D, Dittmar MT, Dietrich U.

Eur J Immunol. 2007 Feb;37(2):501-15.

22.

Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1).

Rodés B, Sheldon J, Toro C, Cuevas L, Pérez-Pastrana E, Herrera I, Soriano V.

J Clin Microbiol. 2007 Jan;45(1):88-92. Epub 2006 Nov 8.

23.

Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain.

Toro C, Jiménez V, Rodríguez C, Del Romero J, Rodés B, Holguín A, Alvarez P, García-Campello M, Gómez-Hernando C, Guelar A, Sheldon J, de Mendoza C, Simón A, Soriano V.

J Med Virol. 2006 Dec;78(12):1599-608.

PMID:
17063510
24.

Mutations affecting the replication capacity of the hepatitis B virus.

Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V.

J Viral Hepat. 2006 Jul;13(7):427-34. Review.

PMID:
16792535
25.

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

Rodés B, Sheldon J, Toro C, Jiménez V, Alvarez MA, Soriano V.

J Antimicrob Chemother. 2006 Apr;57(4):709-13. Epub 2006 Feb 7.

PMID:
16464891
27.

High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

Rodés B, Toro C, Sheldon JA, Jiménez V, Mansinho K, Soriano V.

AIDS. 2006 Jan 2;20(1):127-9.

PMID:
16327332
28.

Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.

Poveda E, Rodés B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V.

J Clin Virol. 2005 Dec;34(4):295-301.

PMID:
16286053
29.

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.

Sheldon JA, Corral A, Rodés B, Mauss S, Rockstroh J, Berger F, Schwarze-Zander C, Soriano V.

AIDS. 2005 Nov 18;19(17):2036-8.

PMID:
16260913
30.

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V.

Antivir Ther. 2005;10(6):727-34.

PMID:
16218172
31.

Treatment response and drug resistance in patients infected with HIV type 1 group O viruses.

Rodes B, de Mendoza C, Rodgers M, Newell A, Jimenez V, Lopez-Brugada RM, Soriano V.

AIDS Res Hum Retroviruses. 2005 Jul;21(7):602-7.

PMID:
16060830
32.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
33.

Enfuvirtide is active against HIV type 1 group O.

Poveda E, Barreiro P, Rodés B, Soriano V.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):583-5.

PMID:
15989465
34.

Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.

Rodés B, Toro C, Jiménez V, Soriano V.

Clin Infect Dis. 2005 Jul 15;41(2):e19-21. Epub 2005 May 31.

PMID:
15983906
35.

Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain.

Toro C, Rodés B, Bassani S, Jiménez V, Tuset C, Brugal MT, de la Fuente L, Soriano V; HTLV Spanish Study Group.

J Clin Virol. 2005 May;33(1):65-70.

PMID:
15797367
36.

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V.

J Med Virol. 2004 Sep;74(1):21-8.

PMID:
15258964
37.

Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection.

Rodés B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, Jimenez V, Wrin T, Bassani S, Soriano V.

AIDS. 2004 May 21;18(8):1109-16.

PMID:
15166526
38.

Are fusion inhibitors active against all HIV variants?

Poveda E, Rodes B, Toro C, Soriano V.

AIDS Res Hum Retroviruses. 2004 Mar;20(3):347-8.

PMID:
15117459
39.

[HIV-2 and HTLV-I/II infections in Spain].

Toro C, Rodés B, Aguilera A, Caballero E, Benito R, Bassani S, Rodríguez C, Tuset C, Ortiz de Lejarazu R, Eirós J, García J, Calderón E, Capote FJ, Vallejo A, Gutiérrez M, Soriano V; Grupo Español para el Estudio del VIH-2 y del HTLV-I/II.

Enferm Infecc Microbiol Clin. 2004 Mar;22(3):177-82. Spanish.

PMID:
14987538
40.

Can drug resistance mutations influence the measurement of plasma HIV-RNA by different viral load techniques?

Poveda E, de Mendoza C, Cuesta M, Toro C, Rodés B, Soriano V.

AIDS Patient Care STDS. 2003 Jul;17(7):321-4.

PMID:
12952733
41.

Transmission of HIV type 1 through blood transfusion from an antibody-negative/p24 antigen-negative donor.

Toro C, Rodés B, Colino F, del Valle Flores M, Poveda E, de Mendoza C, Téllez MJ, Soriano V.

AIDS Res Hum Retroviruses. 2003 Jun;19(6):447-8.

PMID:
12882652
42.

Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase.

Toro C, Rodés B, Mendoza Cd, Soriano V.

Antimicrob Agents Chemother. 2003 May;47(5):1774;author reply 1774-5. No abstract available.

43.
44.

Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

Rodés B, Poveda E, Soriano V.

J Clin Microbiol. 2002 Nov;40(11):4313-6. Erratum in: J Clin Microbiol. 2003 Jan;41(1):527..

45.

Infection with retroviruses other than HIV-1 in Spain: a retrospective analysis for HIV-2, HTLV-I, and/or HTLV-II.

Toro C, Soriano V, Tuset C, Aguilera A, Caballero E, de Lejarazu RO, Rodés B; HIV-2/HTLC Spanish Study Group.

HIV Clin Trials. 2002 Sep-Oct;3(5):397-402.

PMID:
12407489
46.

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

Poveda E, Rodés B, Toro C, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V.

AIDS. 2002 Sep 27;16(14):1959-61. No abstract available.

PMID:
12351957
47.

Prevalence of G333D/E in naive and pretreated HIV-infected patients.

Gallego O, Corral A, de Mendoza C, Rodés B, Soriano V.

AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):857-60.

PMID:
12201908
48.

Clinical impact of HTLV-1 infection in Spain: implications for public health and mandatory screening.

Toro C, Rodés B, Aguilera A, Caballero E, Benito R, Tuset C, García J, De Lejarazu RO, Eirós JM, Calderón E, Rodriguez C, Soriano V; HTLV Spanish Study Group.

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):366-8. No abstract available.

PMID:
12131577
49.

The effect of antiretroviral therapy on HTLV infection.

Machuca A, Rodés B, Soriano V.

Virus Res. 2001 Oct 30;78(1-2):93-100.

PMID:
11520583

Supplemental Content

Support Center